Background/Aims: The peroxisome proliferator-activated receptors (PPARs) are transcriptional regulators of lipid metabolism, activated by unsaturated fatty acids. We investigated independent and interactive effects of PPARγ2 gene PPARG Pro12Ala (rs1801282) andPPARαgene PPARA Leu162Val (rs1800206) genotypes with dietary intake of fatty acids on concentrations of plasma lipids in subjects of whom 47.5% had metabolic syndrome. Methods: The RISCK study is a parallel design, randomised controlled trial. Plasma lipids were quantified at baseline after a 4-week high saturated fatty acids diet and after three parallel 24-week interventions with reference (high saturated fatty acids), high monounsaturated fatty acids and low-fat diets. Single nucleotide polymorphisms were genotyped in 466 subjects. Results: At baseline, the PPARG Ala12allele was associated with increased plasma total cholesterol (n = 378; p = 0.04), LDL cholesterol (p = 0.05) and apoB (p =0.05) after adjustment for age, gender and ethnicity. At baseline, PPARA Leu162Val × PPARG Pro12Ala genotype interaction did not significantly influence plasma lipid concentrations. After dietary intervention, gene-gene interaction significantly influenced LDL cholesterol (p =0.0002) and small dense LDL as a proportion of LDL (p = 0.005) after adjustments. Conclusions: Interaction between PPARG Pro12Ala and PPARA Leu162Valgenotypes may influence plasma LDL cholesterol concentration and the proportion as small dense LDL after a high monounsaturated fatty acids diet.

Keywords:
Peroxisome proliferator-activated receptors, PPARα, PPARγ, Single nucleotide polymorphism, Monounsaturated fatty acid, Low-density lipoprotein cholesterol, Gene-nutrient interaction
1.
Ferré P: The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004;53(suppl 1):S43–S50.
2.
Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649–688.
3.
Lefebvre P, Chinetti G, Fruchart JC, Staels B: Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest 2006;116:571–580.
4.
Semple RK, Chatterjee VK, O’Rahilly S: PPARγ and human metabolic disease. J Clin Invest 2006;116:581–589.
5.
Nielsen R, Pedersen TA, Hagenbeek D, Moulos P, Siersbaek R, Megens E, Denissov S, Børgesen M, Francoijs KJ, Mandrup S, Stunnenberg HG: Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis.Genes Dev 2008;22:2953–2967.
6.
Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284–287.
7.
Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin LJ, Andres R, Roth J, Shuldiner AR: Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 1998;47:1806–1808.
8.
Valve R, Sivenius K, Miettinen R, Pihlajamäki J, Rissanen A, Deeb SS, Auwerx J, Uusitupa M, Laakso M: Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999;84:3708–3712.
9.
Cole SA, Mitchell BD, Hsueh WC, Pineda P, Beamer BA, Shuldiner AR, Comuzzie AG, Blangero J, Hixson JE: The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. IntJObesRelatMetabDisord2000;24:522–524.
10.
Swarbrick MM, Chapman CM, McQuillan BM, Hung J, Thompson PL, Beilby JP: A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. Eur J Endocrinol 2001;144:277–282.
11.
Robitaille J, Brouillette C, Houde A, Lemieux S, Pérusse L, Tchernof A, Gaudet D, Vohl MC: Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet 2004;49:482–489.
12.
Shin MJ, Kanaya AM, Krauss RM: Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians. Atherosclerosis 2008;198:313–319.
13.
Silbernagel G, Stefan N, Hoffmann MM, Machicao-Arano F, Machann J, Schick F, Winkelmann BR, Boehm BO, Häring HU, Fritsche A, März W: The L162V polymorphism of the peroxisome proliferator activated receptor alpha gene (PPARA) is not associated with type 2 diabetes, BMI or body fat composition. Exp Clin Endocrinol Diabetes 2009;117:113–118.
14.
Masugi J, Tamori Y, Mori H, Koike T, Kasuga M: Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000;268:178–182.
15.
Rudkowska I, Verreault M, Barbier O, Vohl MC: Differences in transcriptional activation by the two allelic (L162V polymorphic) variants of PPARalpha after omega-3 fatty acids treatment. PPAR Res 2009;2009:369602.
16.
Jebb SA, Lovegrove JA, Griffin BA, Frost GS, Moore CS, Chatfield MD, Bluck LJ, Williams CM, Sanders TA; RISCK Study Group: Effect of changing the amount and type of fat and carbohydrate on insulin sensitivity and cardiovascular risk: the RISCK (Reading, Imperial, Surrey, Cambridge, and Kings) trial. Am J Clin Nutr 2010;92:748–758.
17.
Alberti KG, Zimmet P, Shaw J: Metabolic syndrome–a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469–480.
18.
Moore C, Gitau R, Goff L, Lewis FJ, Griffin MD, Chatfield MD, Jebb SA, Frost GS, Sanders TA, Griffin BA, Lovegrove JA; RISCK Study Group: Successful manipulation of the quality and quantity of fat and carbohydrate consumed by free-living individuals using a food exchange model. J Nutr 2009;139:1534–1540.
19.
NCBI SNP database http://www.ncbi.nlm.nih.gov/snpbuild132 (accessed November 1, 2011).
20.
Hegsted DM, Ausman LM, Johnson JA, Dallal GE: Dietary fat and serum lipids: an evaluation of the experimental data. Am J Clin Nutr 1993;57:875–883.
21.
Mensink RP, Katan MB: Effect of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women. Lancet 1987;329:122–125.
22.
Kris-Etherton PM, Pearson TA, Wan Y, Hargrove RL, Moriarty K, Fishell V, Etherton TD: High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. Am J Clin Nutr 1999;70:1009–1015.
23.
Krauss RM, Dreon DM:Low-density-lipoprotein subclasses and response to a low-fat diet in healthy men.Am J Clin Nutr1995;62:478S–487S.
24.
Lamarche B, Lemieux I, Despres JP:The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects.Diabetes Metab1999;25:199–211.
25.
Kratz M, Gulbahce E,von Eckardstein A, Cullen P, Cignarella A, Assmann G, Wahrburg U: Dietary mono- and polyunsaturated fatty acids similarly affect LDL size in healthy men and women.J Nutr2002;132:715–718.
26.
Egert S, Kratz M, Kannenberg F, Fobker M, Wahrburg U: Effects of high-fat and low-fat diets rich in monounsaturated fatty acids on serum lipids, LDL size and indices of lipid peroxidation in healthy non-obese men and women when consumed under controlled conditions. Eur J Nutr 2011;50:71–79.
27.
Huang X, Zhao J, Zhao T: Effects of peroxisome proliferator activated receptor-gamma 2 gene Pro12Ala polymorphism on fasting blood lipids: a meta-analysis. Atherosclerosis 2011;215:136–144.
28.
Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE: Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia2000;43:673–680.
29.
Vohl MC, Lepage P, Gaudet D, Brewer CG, Bétard C, Perron P, Houde G, Cellier C, Faith JM, Després JP, Morgan K, Hudson TJ: Molecular scanning of the human PPARa gene: association of the L162V mutation with hyperapolipoproteinbetalipoproteinemia. J Lipid Res2000;41:945–952.
30.
Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P, Ehrenborg E: Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 2003;23:637–643.
31.
Sparsø T, Hussain MS, Andersen G, Hainerova I, Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O: Relationships between the functional PPARalpha Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5,799 middle-aged white people. Mol Genet Metab 2007;90:205–209.
32.
Nielsen EM, Hansen L, Echwald SM, Drivsholm T, Borch-Johnsen K, Ekstrøm CT, Hansen T, Pedersen O: Evidence for an association between the Leu162Val polymorphism of the PPARalpha gene and decreased fasting serum triglyceride levels in glucose tolerant subjects. Pharmacogenetics 2003;13:417–423.
33.
Aberle J, Hopfer I, Beil FU, Seedorf U: Association of peroxisome proliferator-activated receptor delta +294T/C with body mass index and interaction with peroxisome proliferator-activated receptor alpha L162V. Int J Obes Metab Disord 2006;30:1709–1713.
34.
Vidal-Puig A, Jimenez-Liñan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Moller DE: Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 1996;97:2553–2561.
35.
Patsouris D, Reddy JK, Müller M, Kersten S: Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 2006;147:1508–1516.
36.
Memisoglu A, Hu FB, Hankinson SE, Manson JE, De Vivo I, Willett WC, Hunter DJ: Interaction between a peroxisome proliferator-activated receptor γ gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet 2003;12:2923–2929.
37.
Luan J, Browne PO, Harding AH, Halsall DJ, O’Rahilly S, Chatterjee VK, Wareham NJ: Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 2001;50:686–689.
38.
Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV: Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999;3:397–403.
39.
Tai ES, Corella D, Demissie S Cupples LA, Coltell O, Schaefer EJ, Tucker KL, Ordovas JM; Framingham Heart Study: Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutr 2005;135:397–403.
40.
Paradis AM, Fontaine-Bisson B, Bossé Y, Robitaille J, Lemieux S, Jacques H, Lamarche B, Tchernof A, Couture P, Vohl MC: The peroxisome proliferator-activated receptor alpha Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men. Am J Clin Nutr 2005;81:523–530.
41.
Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547–1554.
42.
Ovalle F, Bell DS: Lipoprotein effects of different thiazolidinediones in clinical practice. Endocr Pract 2002;8:406–410.
43.
Shah A, Rader DJ, Millar JS: The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010;210:35–40.
44.
Klopotek A, Hirche F, Eder K: PPAR gamma ligand troglitazone lowers cholesterol synthesis in HepG2 and Caco-2 cells via a reduced concentration of nuclear SREBP-2. Exp Biol Med (Maywood) 2006;231:1365–1372.
45.
Kast-Woelbern HR, Dana SL, Cesario RM, Sun L, de Grandpre LY, Brooks ME, Osburn DL, Reifel-Miller A, Klausing K, Leibowitz MD: Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis. J Biol Chem 2004;279:23908–23915.
46.
König B, Koch A, Spielmann J, Hilgenfeld C, Stangl GI, Eder K: Activation of PPARalpha lowers synthesis and concentration of cholesterol by reduction of nuclear SREBP-2. Biochem Pharmacol 2007;73:574–585.
47.
Hamada T, Kotani K, Tsuzaki K, Sano Y, Murata T, Tabata M, Sato S, Sakane N: Association of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene with small dense low-density lipoprotein in the general population. Metabolism 2007;56:1345–1349.
48.
Bouchard-Mercier A, Godin G, Lamarche B, Pérusse L, Vohl MC: Effects of peroxisome proliferator-activated receptors, dietary fat intakes and gene-diet interactions on peak particle diameters of low-density lipoproteins. J Nutrigenet Nutrigenomics 2011;4:36–48.
49.
Caslake MJ, Packard CJ, Gaw A, Murray E, Griffin BA, Vallance BD, Shepherd J: Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993;13:702–711.
50.
Berneis KK, Krauss RM: Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2001;43:1363–1379.
51.
Aldhoon B, Zamrazilová H, Aldhoon Hainerová I, Srámková P, Spálová J, Kunesová M, Bendlová B, Hainer V: Role of the PPARα Leu162Val and PPARγ2 Pro12Ala gene polymorphisms in weight change after 2.5-year follow-up in Czech obese women. Folia Biologica (Praha) 2010;56:116–123.
52.
Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264–1272.
53.
Morrison AC, Bare LA, Chambless LE, Ellis SG, Malloy M, Kane JP, Pankow JS, Devlin JJ, Willerson JT, Boerwinkle E: Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2007;166:28–35.
54.
Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, Hirschhorn JN, Berglund G, Hedblad B, Groop L, Altshuler DM, Newton-Cheh C, Orho-Melander M: Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008;358:1240–1249.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.